Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2021-01-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于2021年日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding the expected daily related party transactions for the year 2021. It includes details about the nature, estimated amounts, and approval process of these related party transactions. The document references board meeting resolutions, independent directors' opinions, and compliance with regulatory requirements. It does not contain financial statements or comprehensive financial performance data. The document is an announcement of expected related party transactions, which is a regulatory disclosure typically filed as a general regulatory announcement rather than a full financial report or management discussion. The document length is 4309 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement about related party transactions and not a full report or financial statement.
2021-01-07 Chinese
独立董事关于第三届董事会第十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the 14th meeting of the third board of directors of Betta Pharmaceuticals Co., Ltd. It includes independent opinions on proposals such as profit distribution, nomination of directors, related party transactions, use of raised funds, and cash management. The document is a formal statement of independent directors' views on board meeting agenda items, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive content and opinions rather than just announcing a report's release. It is not a management report or earnings release as it focuses on governance and board meeting matters. The document fits best under Board/Management Information (MANG) as it relates to board meeting decisions and director nominations.
2021-01-07 Chinese
对外担保制度
Governance Information Classification · 95% confidence The document is titled '对外担保制度' (External Guarantee System) of 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It details the internal control policies, procedures, approval processes, risk management, and disclosure requirements related to the company's external guarantees. The content is a governance and compliance document outlining rules and responsibilities for external guarantees, referencing relevant laws, regulations, and listing rules, including the Hong Kong Stock Exchange Listing Rules. It does not contain financial statements, audit opinions, earnings data, or meeting materials. It is a detailed internal governance policy document rather than a report or announcement. Therefore, the most appropriate classification is Governance Information (CGR).
2021-01-07 Chinese
第三届监事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th meeting of the 3rd Supervisory Board of Betta Pharmaceuticals Co., Ltd. It includes voting results on various proposals related to the issuance and listing of H shares on the Hong Kong Stock Exchange, use of raised funds, amendments to supervisory rules, and related party transactions. The document is a formal meeting resolution announcement, not a financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on governance and corporate actions requiring shareholder approval. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or supervisory bodies. The document length (5789 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive board meeting resolution announcement.
2021-01-07 Chinese
第三届董事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 14th meeting of the third board of directors of Betta Pharmaceuticals Co., Ltd. It includes approvals related to the issuance and listing of H shares on the Hong Kong Stock Exchange, authorization of the board to handle related matters, amendments to company bylaws and governance documents, nomination of directors, approval of related party transactions, and plans for the use of raised funds. The document also mentions that these resolutions will be submitted to the 2021 first extraordinary general meeting of shareholders for approval. The content is focused on board meeting decisions and management authorizations rather than the full text of a report or financial statements. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement. The document is a formal disclosure of board/management decisions and changes, including board nominations and governance amendments. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2021-01-07 Chinese
独立董事工作制度
Governance Information Classification · 95% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System'. It details the rules, conditions, nomination, election, duties, rights, and working conditions of independent directors at 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). The content focuses on governance structure, director responsibilities, and compliance with laws and stock exchange rules. There are no financial statements, earnings data, or audit results. It is a governance-related document outlining internal rules and practices for board members, specifically independent directors. Therefore, it fits the category of Governance Information (CGR). The document length is 6147 characters, which is substantive and not a mere announcement or certification, supporting classification as CGR rather than RNS or RPA.
2021-01-07 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.